US Residents
This site is intended for non-US residents only.

Prosigna is now included in International clinical practice guidelines

Managing patients with
early-stage breast cancer…
…begins with a highly
accurate assessment of risk
Mastering the science
of tumor biology
Prosigna uses the PAM50 gene
signature to translate tumor
biology into your patient's individualized
prognostic score.
Achieving precise results
Advanced technology generates precise,
reproducible prognostic information in
local qualified laboratories.
Proven risk assessment
you can trust
Prosigna reliably identifies
your patient's 10-year risk
of distant recurrence
and subtype.
Proceed with confidence